CAMBRIDGE, Mass., June 22 /PRNewswire/ -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, today announced that it will be presenting at the Jefferies Life Science Conference in New York. Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, will provide an overview of the Company and discuss the Company’s strategy for discovering and developing first in class therapeutics that modulate sirtuins, the body’s own health-promoting proteins. His presentation will be delivered at 1:45pm EST on Wednesday, June 28th, 2006 and will be webcast on: http://www.wsw.com/webcast/jeff11/sirtris.
About Sirtuins
Sirtuins are a recently-discovered family of enzymes that promote the body’s natural defense against disease. There are seven human sirtuins (SIRT1-7), each having a different sub-cellular localization. Critical to the survival of organisms in adverse conditions, sirtuins are fundamental in the biological processes of most life forms. Sirtuins are attractive drug targets since some have a specialized function in mitochondrial activity which may be therapeutically beneficial for metabolic and neurological diseases. By harnessing a natural process, sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging, such as diabetes, in a new way.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging like metabolic and neurological diseases.
Sirtris Pharmaceuticals was founded by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal, and has raised a total of $82 million since inception. Its investors include Polaris Venture Partners, TVM Capital, Cardinal Partners, Skyline Ventures, Three Arch Partners, The Wellcome Trust, Bessemer Venture Partners, Novartis Bioventures Fund, Cargill Ventures, Genzyme Ventures, QVT Fund LP, Cycad Group, Hunt Ventures, Red Abbey, and Alexandria Real Estate Equities, Inc. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.
Media Contact: Michelle Dipp 617-252-6920
Sirtris Pharmaceuticals
CONTACT: Michelle Dipp of Sirtris Pharmaceuticals, +1-617-252-6920
Web site: http://www.sirtrispharma.com//
